InsiderGlobe

KLRS

insider transactions

Kalaris Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).

30D 90D 1Y

Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 2 different insiders made open-market purchases in the last 365 days, totalling $6.2M.

Net shares · 365d

+722.2K

724.1K buy · 1.9K sell

Net value · 365d

$6.2M

$6.2M in · $12.9K out

Sentiment · 365d

Net buying

100% buying · 0% selling

Open-market trades · 365d

3

724.1K buy · 1.9K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

Transactions · 365d

Open-market Buys Sells All types

Buy Sell Non-market (grant · exercise · gift)

About KLRS insider trading

This page tracks insider transactions for Kalaris Therapeutics, Inc. (KLRS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.